Value of Oral APX3330 for Diabetic Retinopathy Progression w/ Daniel Su, MD

At ARVO 2024, Daniel Su, MD describes the promise of APX3330 for delaying or preventing diabetic retinopathy progression in a post-hoc analysis of the ZETA-1 trial.
A posthoc analysis of the phase 2 ZETA-1 trial showed a reduction in binocular ≥3-step and ≥4-step worsening in APX3330 treated subjects compared with placebo, supporting its role as a promising oral agent for delaying the progression of NPDR to PDR.
"The idea of an oral agent is very attractive. It’s something patients can continue to be on treatment, even though they may not return for an in-office injection,” Su told HCPLive.
Highlights
0:07 Impact of oral agent for DR
2:12 Post-hoc analysis of ZETA-1
5:17 Key findings
7:53 Importance of the findings
Read more here: www.hcplive.com/view/daniel-s...
Check out our full ARVO coverage: www.hcplive.com/conference/arvo
#ophthalmology #diabeticretinopathy #conference